Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 20Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Fallopian Tube Neoplasms 13Colorectal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Hepatocellular 9Melanoma 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Breast Neoplasms 6Urinary Bladder Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Carcinoma, Renal Cell 5Neoplasms 4Uterine Cervical Neoplasms 3Sezary Syndrome 3Sarcoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3

Interventions

Nutrition Assessment 3Transcranial Direct Current Stimulation 2urinastatin 1tocilizumab 1rimabotulinumtoxinB 1X-Rays 1Vitamin B 6 1Vitamin B 12 1Standard of Care 1Saline Solution 1Rosuvastatin Calcium 1Resistance Training 1Practice Guidelines as Topic 1Phenylephrine 1Palliative Care 1Norepinephrine 1Neuropsychological Tests 1Music Therapy 1Massage 1Lysine Acetyltransferase 5 1Infliximab 1Immunoglobulin G 1Hematologic Tests 1Folic Acid 1Extracorporeal Shockwave Therapy 1Exergaming 1Enoxaparin 1Disulfides 1Dialectical Behavior Therapy 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stroke × Immunoglobulin G × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡